Literature DB >> 7937769

Transcriptional activation in vitro by the human immunodeficiency virus type 1 Tat protein: evidence for specific interaction with a coactivator(s).

C Z Song1, P M Loewenstein, M Green.   

Abstract

The Tat protein encoded by human immunodeficiency virus type 1 is a strong transcriptional activator of gene expression from the viral long terminal repeat and is essential for virus replication. We have investigated the molecular mechanism of Tat trans-activation by using a cell-free transcription system. We find that the trans-activation domain of Tat, amino acid residues 1-48 [Tat-(1-48)], can inhibit specifically--i.e., "squelch," transcriptional activation by full-length Tat [Tat-(1-86)]. Squelching depends upon the functional integrity of the Tat trans-activation domain because the mutant [Ala41]Tat-(1-48), which is defective in Tat trans-activation in vivo and in vitro, does not squelch in vitro Tat trans-activation. Inhibition is selective because Tat-activated transcription, but not Tat-independent transcription, is squelched. Preincubation experiments with Tat or Tat-(1-48) and nuclear extracts show that the trans-activation region of Tat can interact with cellular coactivator(s) required for Tat trans-activation and that this interaction can occur in the absence of the human immunodeficiency virus long terminal repeat promoter. Furthermore, the putative coactivator(s) mediating trans-activation by Tat differ from those mediating trans-activation by the acidic activator VP16, as shown by reciprocal squelching experiments in vitro. Our results suggest that specific cellular coactivator(s) are required for mediating activated transcription by human immunodeficiency virus type 1 Tat.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937769      PMCID: PMC44811          DOI: 10.1073/pnas.91.20.9357

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  New human gene encoding a positive modulator of HIV Tat-mediated transactivation.

Authors:  H Shibuya; K Irie; J Ninomiya-Tsuji; M Goebl; T Taniguchi; K Matsumoto
Journal:  Nature       Date:  1992-06-25       Impact factor: 49.962

2.  Mechanism of action of a yeast activator: direct effect of GAL4 derivatives on mammalian TFIID-promoter interactions.

Authors:  M Horikoshi; M F Carey; H Kakidani; R G Roeder
Journal:  Cell       Date:  1988-08-26       Impact factor: 41.582

3.  Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I.

Authors:  M Siekevitz; S F Josephs; M Dukovich; N Peffer; F Wong-Staal; W C Greene
Journal:  Science       Date:  1987-12-11       Impact factor: 47.728

4.  Response of individual adenovirus promoters to the products of the E1A gene.

Authors:  C V Dery; C H Herrmann; M B Mathews
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

5.  Initiation of transcription by RNA polymerase II: a multi-step process.

Authors:  L Zawel; D Reinberg
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1993

6.  Eukaryotic activators function during multiple steps of preinitiation complex assembly.

Authors:  B Choy; M R Green
Journal:  Nature       Date:  1993-12-09       Impact factor: 49.962

7.  Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.

Authors:  S J Madore; B R Cullen
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 8.  Does HIV-1 Tat induce a change in viral initiation rights?

Authors:  B R Cullen
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Identification of a coactivator that increases activation of transcription by serum response factor and GAL4-VP16 in vitro.

Authors:  H Zhu; R Pyrwes
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

10.  In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.

Authors:  K T Jeang; R Chun; N H Lin; A Gatignol; C G Glabe; H Fan
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more
  9 in total

1.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

2.  A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription.

Authors:  H Xiao; Y Tao; J Greenblatt; R G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

3.  Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  C Z Song; P M Loewenstein; M Green
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  In vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP.

Authors:  L Yu; P M Loewenstein; Z Zhang; M Green
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  The adenovirus E1A repression domain disrupts the interaction between the TATA binding protein and the TATA box in a manner reversible by TFIIB.

Authors:  C Z Song; P M Loewenstein; K Toth; Q Tang; A Nishikawa; M Green
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

7.  Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB.

Authors:  N M Rank; P F Lambert
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.

Authors:  S L Schafer; J Vlach; P M Pitha
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Preventive effect of ascorbic acid against biological function of human immunodeficiency virus trans-activator of transcription.

Authors:  Takuma Hayash
Journal:  J Intercult Ethnopharmacol       Date:  2016-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.